Clinical Trial Update: Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on pralatrexate plus romidepsin in relapsed/refractory lymphoid malignancies and multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Lymphoid Malignancies
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Pralatrexate (pralatrexate)
• Romidepsin (romidepsin)

Snippet

Sponsor: Jennifer Amengual | Conditions: Lymphoid Malignancies, Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED